FDA approves Kite's manufacturing process change, reducing Yescarta® CAR T-cell therapy turnaround time from 16 to 14 days.

Kite, a Gilead company, has received approval from the U.S. Food and Drug Administration (FDA) for a manufacturing process change that reduces the median turnaround time for its Yescarta® CAR T-cell therapy. The approval shortens the production time for Yescarta from 16 days to 14 days, improving access to the treatment for patients with relapsed or refractory large B-cell lymphoma.

January 30, 2024
6 Articles